PMID- 34736419
OWN - NLM
STAT- MEDLINE
DCOM- 20220310
LR  - 20220310
IS  - 1471-2369 (Electronic)
IS  - 1471-2369 (Linking)
VI  - 22
IP  - 1
DP  - 2021 Nov 4
TI  - Clinical efficacy and safety of full-dose versus half-dose corticosteroids plus 
      leflunomide for IgA nephropathy.
PG  - 364
LID - 10.1186/s12882-021-02555-z [doi]
LID - 364
AB  - BACKGROUND: The results of leflunomide (LEF) in patients with IgA nephropathy 
      (IgAN) were inconsistent. METHODS: A total of 149 kidney biopsy-confirmed IgAN 
      patients with an estimated glomerular filtration rate 
      (eGFR) >/= 50 ml/min/1.73 m(2) and protein excretion levels >/=0.75 g/d were 
      enrolled, with 65 subjects receiving half-dose CS plus LEF (LEF group), and the 
      84 counterpart patients accepting full-dose corticosteroid (Full CS group). The 
      primary outcomes included the complete remission (CR) rates and incidence of 
      adverse events (AEs). The secondary outcomes were the overall remission (OR) 
      rates and a combined event (eGFR reduced >/=30%, end-stage renal disease [ESRD], 
      hemodialysis, peritoneal dialysis or kidney transplantation). RESULTS: During the 
      18 months of follow-up, the CR rates were 72 and 64% in the LEF and Full CS 
      groups (P = 0.299), respectively. The proportion of patients with OR rates in the 
      LEF group and Full CS group was 89% versus 75%, respectively (P = 0.027). Serious 
      AEs were observed only in the Full CS group (P = 0.017). The incidences of total 
      AEs (P = 0.036) and infections (P = 0.024) were lower in the LEF group than in 
      the Full CS group. CONCLUSIONS: LEF combined with half-dose CS is superior to 
      full-dose CS in the treatment of IgAN.
CI  - (c) 2021. The Author(s).
FAU - Li, Yebei
AU  - Li Y
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      No. 1, Minde Road, Donghu District, Nanchang, 330006, P.R. China.
FAU - Xiong, Yi
AU  - Xiong Y
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      No. 1, Minde Road, Donghu District, Nanchang, 330006, P.R. China.
FAU - Huang, Tianlun
AU  - Huang T
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      No. 1, Minde Road, Donghu District, Nanchang, 330006, P.R. China.
FAU - Liu, Xin
AU  - Liu X
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      No. 1, Minde Road, Donghu District, Nanchang, 330006, P.R. China.
FAU - Xu, Gaosi
AU  - Xu G
AD  - Department of Nephrology, The Second Affiliated Hospital of Nanchang University, 
      No. 1, Minde Road, Donghu District, Nanchang, 330006, P.R. China. 
      gaosixu@163.com.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20211104
PL  - England
TA  - BMC Nephrol
JT  - BMC nephrology
JID - 100967793
RN  - 0 (Adrenal Cortex Hormones)
RN  - G162GK9U4W (Leflunomide)
SB  - IM
MH  - Adrenal Cortex Hormones/*administration & dosage/adverse effects
MH  - Adult
MH  - Cohort Studies
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Glomerulonephritis, IGA/*drug therapy
MH  - Humans
MH  - Leflunomide/*administration & dosage/adverse effects
MH  - Male
MH  - Retrospective Studies
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC8567572
OTO - NOTNLM
OT  - Corticosteroids
OT  - IgA nephropathy
OT  - Leflunomide
OT  - Renin-angiotensin system blockers
COIS- The authors declare that they have no competing interests.
EDAT- 2021/11/06 06:00
MHDA- 2022/03/11 06:00
PMCR- 2021/11/04
CRDT- 2021/11/05 05:30
PHST- 2021/03/01 00:00 [received]
PHST- 2021/06/19 00:00 [accepted]
PHST- 2021/11/05 05:30 [entrez]
PHST- 2021/11/06 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/11/04 00:00 [pmc-release]
AID - 10.1186/s12882-021-02555-z [pii]
AID - 2555 [pii]
AID - 10.1186/s12882-021-02555-z [doi]
PST - epublish
SO  - BMC Nephrol. 2021 Nov 4;22(1):364. doi: 10.1186/s12882-021-02555-z.